What's New:
November 22, 2008 12:36:29 PM EST

Top News Stories

Story Image

Pfizer's Ills And Cures In 2008
Saturday November 22, 2008 07:46:00 EST

(RTTNews) - Dogged by patent expirations, regulatory setbacks and high-profile drug trial failures, 2008 has been a whirlwind year for Pfizer. The drug titan is seeking to cure its ills with serious retrenching measures and by shifting its research focus from heart disease, obesity, and bone health to more lucrative fields such as cancer and Alzheimer's.

With patents covering some of Pfizer's key drugs set to expire in the next few years, the company is accelerating its pipeline to plug the impending holes in its balance sheet. According to Prudential Equity Group's Timothy Anderson, drugs, which make up 41% of Pfizer's sales, are slated to lose patent protection between 2010 and 2012. The drugs going off the patent between 2010 and 2012 are Aricept, Lipitor, Viagra, Detr (continued...)

.

News By









Major Indices

Get Basic Chart
Desc Last Change (%)
DOW 8,046.42 494.13 (6.54%)
NASDAQ 1,384.35 68.23 (5.18%)
S&P 500 800.03 47.59 (6.32%)
Russell 2000 406.54 21.23 (5.51%)
DOW Transports 3,122.75 133.76 (4.48%)
DOW Utilities 366.34 30.61 (9.12%)

Trading Corner